Gabapentin Capsule
Product Images NDC 80425-0286

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 80425-0286). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description (Description)

Chemical structure diagram of gabapentin showing its molecular framework with cyclohexane ring and functional groups including an amine and a carboxyl group.*

FDA Label Image

Label 1 (Gabapentin 80425 0286 01)

Gabapentin 400 mg capsule packaging label from Advanced Rx Pharmacy of Tennessee, LLC. The label includes storage instructions to keep the product at 20°-25°C, a comparison to Neurontin, and batch information with expiration date 4/3/2024. The package contains 30 capsules.*

FDA Label Image

Label 2 (Gabapentin 80425 0286 02)

Gabapentin 400 mg capsule packaging label by Advanced Rx Pharmacy of Tennessee, LLC. The label includes storage instructions, a lot number, expiration date (4/3/2024), and mentions comparison to Neurontin. It specifies oral route and is marked #60 capsules.*

FDA Label Image

Label 3 (Gabapentin 80425 0286 03)

Gabapentin 400 mg capsule packaging label from Advanced Rx Pharmacy of Tennessee, LLC. The label includes product identification, storage instructions (20°-25°C), and lot expiration date information. It states 'Compare to Neurotin' with relevant NDC codes listed. The package contains 90 capsules and features barcodes and a QR code.*

FDA Label Image

Fig 1 (Fig 1)

A line graph depicting mean pain score over an 8-week period comparing placebo and Gabapentin at 3,600 mg/day. The x-axis shows weeks from baseline through week 8, divided into a 4-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing pain trend compared to placebo.*

FDA Label Image

Fig 2 (Fig 2)

A line graph showing mean pain scores over a 7-week period with a 3-week dose titration and a 4-week fixed dose phase. The graph compares placebo and two Gabapentin dose groups (1,800 mg/day and 2,400 mg/day) with pain scores plotted against weeks.*

FDA Label Image

Fig 3 (Fig 3)

A bar chart comparing percentage values from two separate studies. Study 1 shows bars labeled PBO and GBP 3,600 with values at 12% and 29% respectively. Study 2 shows bars labeled PBO, GBP 1,800, and GBP 2,400 with values around 14%, 32%, and 34% respectively. Statistical significance markers indicate p-values less than 0.01 and 0.001.*

FDA Label Image

Fig 4 (Fig 4)

A scatter plot graph showing the percentage difference on the y-axis versus daily doses in mg on the x-axis for Gabapentin. The graph includes data points from three studies labeled a, b, and c, with daily doses ranging roughly from 600 mg to 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.